Sildenafil Tablet, Film Coated
Product Images NDC 71205-267

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sildenafil (NDC 71205-267). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure Of Sildenafil Citrate (Image 1)

Chemical structure of Sildenafil, showing the molecular arrangement of atoms and bonds typical for this active pharmaceutical ingredient.*

FDA Label Image

71205-267-30 (Image 10)

Sildenafil 50 mg film-coated tablets label from Proficient Rx LP, showing a 30-count package. The label states the active ingredient is sildenafil citrate equivalent to 50 mg sildenafil per tablet. The tablets are described as white to off-white, film-coated, modified oval-shaped with debossed markings. Manufacturer is Pliva Hrvatska d.o.o., Zagreb, Croatia.*

FDA Label Image

Figure1 (Image 2)

A line graph depicting systolic blood pressure (mmHg) over time post-dose (hours) comparing Sildenafil 100 mg and placebo. The x-axis shows time points from pre-dose to 24 hours, while the y-axis measures systolic blood pressure changes. The graph illustrates pressure variations for both Sildenafil and placebo groups within this timeframe.*

FDA Label Image

Figure2 (Image 3)

Line graph showing change in systolic blood pressure (SBP) over time postdose (hours) comparing two treatments: Doxazosin with placebo and Doxazosin with Sildenafil 25 mg. The y-axis represents change in SBP (mm Hg) and the x-axis is time postdose (hours) from 0 to 8.*

FDA Label Image

Figure3 (Image 4)

A line graph comparing the change in systolic blood pressure (SBP) in mmHg over time (hours postdose) between two treatments: Doxazosin plus Placebo and Doxazosin plus Sildenafil 50 mg. The graph shows separate trend lines for each treatment group across an 8-hour postdose period.*

FDA Label Image

Figure4 (Image 5)

A line graph comparing blood pressure changes (mmHg) over 8 hours after dosing between two groups: 'Doxazosin + Sildenafil 100 mg' and 'Doxazosin + Placebo'. The graph shows time after dosing on the x-axis (0 to 8 hours) and blood pressure change on the y-axis (-50 to 40 mmHg), indicating differences in blood pressure response between the two treatments.*

FDA Label Image

Figure5 (Image 6)

This graph depicts plasma concentrations of sildenafil over time post-dose in hours. It shows the concentration (ng/mL) on the vertical axis and time post-dose from 0 to 24 hours on the horizontal axis, illustrating the pharmacokinetic profile of a commercial sildenafil tablet.*

FDA Label Image

Figure6 (Image 7)

Two bar charts comparing the effect of Sildenafil Citrate and placebo on maintenance of erection by baseline score. The x-axis shows baseline scores from 0 to 5, and the y-axis shows the percentage of patients at endpoint. Bars are grouped by different categories labeled 0 through 5 in a legend, showing variations in patient percentage for each baseline score.*

FDA Label Image

Figure7 (Image 8)

A bar chart comparing the percentage of patients reporting improvement across four treatment groups: placebo, sildenafil 25 mg, sildenafil 50 mg, and sildenafil 100 mg. The chart shows an increasing trend in patient-reported improvement with higher sildenafil doses, ranging from 24% in the placebo group to 82% in the 100 mg sildenafil group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.